Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Drops By 59.4%

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 69,800 shares, a drop of 59.4% from the March 31st total of 171,800 shares. Based on an average daily volume of 701,300 shares, the short-interest ratio is currently 0.1 days.

Astellas Pharma Stock Performance

Shares of OTCMKTS:ALPMY traded up $0.01 during midday trading on Friday, hitting $9.55. The stock had a trading volume of 452,047 shares, compared to its average volume of 301,920. The company has a market capitalization of $17.28 billion, a PE ratio of 24.28, a P/E/G ratio of 1.64 and a beta of 0.32. Astellas Pharma has a 1 year low of $9.15 and a 1 year high of $16.91. The stock has a 50 day moving average price of $10.53 and a two-hundred day moving average price of $11.45. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 25th. The company reported $0.11 earnings per share (EPS) for the quarter. Astellas Pharma had a net margin of 0.08% and a return on equity of 6.39%. The company had revenue of $2.79 billion for the quarter. As a group, equities analysts predict that Astellas Pharma will post 0.23 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.